MicroBrain Science: Se espera que los ingresos del primer semestre aumenten alrededor del 34% al 37% en comparación con el mismo período del año anterior.
Weicai Brain Science announced that its expected revenue for the first half of the year will reach 400 million to 410 million yuan, a year-on-year increase of about 34% to 37%. Revenue growth is mainly due to breakthroughs in overseas business, with revenue expected to increase by about 70% to 90%; the market share of intracranial atherosclerotic stenosis products has increased; spring coil products have benefited from winning the bid for centralized procurement, accelerating the development of blank markets; and multiple acute ischemic stroke and pathway products have accelerated hospital access and clinical use.
Ver originales
Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.
MicroBrain Science: Se espera que los ingresos del primer semestre aumenten alrededor del 34% al 37% en comparación con el mismo período del año anterior.
Weicai Brain Science announced that its expected revenue for the first half of the year will reach 400 million to 410 million yuan, a year-on-year increase of about 34% to 37%. Revenue growth is mainly due to breakthroughs in overseas business, with revenue expected to increase by about 70% to 90%; the market share of intracranial atherosclerotic stenosis products has increased; spring coil products have benefited from winning the bid for centralized procurement, accelerating the development of blank markets; and multiple acute ischemic stroke and pathway products have accelerated hospital access and clinical use.